Benitec Biopharma (BNTC) Q2 2026 earnings summary

Executive summary

• Focused on developing genetic medicines using a proprietary DNA-directed RNA interference (ddRNAi) platform, with lead candidate BB-301 for Oculopharyngeal Muscular Dystrophy (OPMD).

• BB-301 has Orphan Drug Designation in the US and EU, and received Fast Track Designation from the FDA in November 2025; Phase 1b/2a trial ongoing with positive interim results and no severe adverse events reported.

• Four patients in Cohort 1 of the BB-301 Phase 1b/2a study completed 12-month follow-up, all showing durable response, with Patient 1 demonstrating continued improvement at 24 months.

• No products approved or revenue from product sales; operations funded through equity financing.

Financial highlights

• Net loss of $11.8 million for the quarter and $20.8 million for the six months ended December 31, 2025, compared to $9.6 million and $14.6 million for the same periods in 2024.

• Operating expenses rose to $13.4 million for the quarter and $23.2 million for the six months, driven by increased share-based compensation and salaries.

• Cash and cash equivalents totaled $189 million as of December 31, 2025.

• No outstanding borrowings or credit facilities.

Outlook and guidance

• Cash position expected to fund operations for at least the next twelve months.

• Continued operating losses anticipated as R&D and clinical activities progress.

• Plans to engage with the FDA in mid-2026 to confirm pivotal study design for BB-301; interim Cohort 2 results expected mid-2026.